|
|
Article: Dynogen awarded broad United States patent relating to treatment of lower urinary tract disorders.
- Article from:
- BIOTECH Patent News
- Article date:
- January 1, 2005
CopyrightCOPYRIGHT 2005 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dynogen Pharmaceuticals, Inc. (Waltham, MA) has been awarded United States Patent 6,846,823 (the '823 patent) related to the use of DDP225, formerly known as MCI225, for the treatment of lower urinary tract disorders. The claims of this patent cover the use of a broad class of thieno(2,3-d)pyrimidine derivatives, including DDP225, for the treatment of urinary frequency, urinary urgency, nocturia (nighttime urination) and enuresis (bedwetting). These symptoms are associated with overactive bladder (OAB), the irritative symptoms of benign prostatic hyperplasia (BPH), interstitial cystitis and other lower urinary tract disorders. Dynogen is studying DDP225 in human clinical ...